PIK3CA E453K
Gene Variant Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene PIK3CA
Variant E453K
Impact List missense
Protein Effect gain of function
Gene Variant Descriptions PIK3CA E453K lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). E453K results in increased phosphorylation of Akt and Mek1/2, enhanced cell survival, increased cell proliferation and migration, and is transforming in culture (PMID: 26627007, PMID: 29533785, PMID: 34779417).
Associated Drug Resistance
Category Variants Paths

PIK3CA mutant PIK3CA act mut PIK3CA E453K

PIK3CA mutant PIK3CA exon8 PIK3CA E453K

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_006218.4
gDNA chr3:g.179210291G>A
cDNA c.1357G>A
Protein p.E453K
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_006218 chr3:g.179210291G>A c.1357G>A p.E453K RefSeq GRCh38/hg38
XM_006713658.5 chr3:g.179210291G>A c.1357G>A p.E453K RefSeq GRCh38/hg38
NM_006218.3 chr3:g.179210291G>A c.1357G>A p.E453K RefSeq GRCh38/hg38
NM_006218.4 chr3:g.179210291G>A c.1357G>A p.E453K RefSeq GRCh38/hg38
XM_006713658.4 chr3:g.179210291G>A c.1357G>A p.E453K RefSeq GRCh38/hg38
XM_011512894.2 chr3:g.179210291G>A c.1357G>A p.E453K RefSeq GRCh38/hg38
XM_006713658 chr3:g.179210291G>A c.1357G>A p.E453K RefSeq GRCh38/hg38
XM_011512894 chr3:g.179210291G>A c.1357G>A p.E453K RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
PIK3CA E453K breast cancer resistant Buparlisib Preclinical - Cell culture Actionable In a preclinical study, breast cancer cells expressing PIK3CA E453K demonstrated resistance to treatment with Buparlisib (BKM120) in culture (PMID: 29636477). 29636477
PIK3CA E453K lung squamous cell carcinoma no benefit Taselisib Case Reports/Case Series Actionable In a Phase I (SWOG S1400B) trial, Taselisib (GDC-0032) treatment did not meet its primary endpoint for response rate in patients with lung squamous cell carcinoma harboring PIK3CA mutations, resulting in no response in a patient harboring PIK3CA E453K (PMID: 31158500; NCT02785913). 31158500
PIK3CA E453K breast cancer decreased response LY294002 Preclinical - Cell culture Actionable In a preclinical study, a breast cancer cell line expressing PIK3CA E453K was less sensitive to LY294002 treatment compared to cells overexpressing wild-type PIK3CA or PIK3CA E418K in culture (PMID: 38909932). 38909932